Advertisement
Articles
Subscribe to Drug Discovery & Development Articles

The Lead

Rating U.S. Drug Development Programs

August 20, 2014 | by Chris Plaford, CFA, Chief Executive Officer, Claravant Analytics LLC | Comments

According to industry estimates, the majority of drugs in development will never make it to FDA approval. While a lack of efficacy is often a key factor, many clinical programs are derailed due to avoidable setbacks that can cause delays and significantly increase costs. Read more...

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Small Molecules, Stem Cells Can Improve Hearing

August 18, 2014 3:14 pm | by Cynthia Fox, Science Editor | Comments

A scientist has found that a compound, LY-411575, can restore 20% of hearing in deaf mice, or ten decibels. Since electroacoustic hearing aids, at best, improve hearing by five decibels, there is a “good chance” the work will lead to help for deafened patients.

TOPICS:

Developing Multi-Functional Anti-Inflammatory Drugs

July 24, 2014 10:44 am | by Gur Roshwalb, M.D., Chief Executive Officer of Celsus Therapeutics | Comments

Recent years have witnessed the development of novel, non-steroidal anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAIDs) focusing has been on one of the most sought-after pharmaceutical targets in inflammation research: the secretory phospholipase A2 family. Read more...

TOPICS:

Reoviruses: The Discovery of Their Potential in Cancer Therapeutics

July 17, 2014 10:23 am | by Brad Thompson, Ph.D., President and Chief Executive Officer of Oncolytics Biotech | Comments

Reoviruses - first isolated in 1951 - are benign viruses with an important property: they are oncolytic, meaning they are capable of infecting and destroying many kinds of cancer cells. The story of how this discovery was made is an exciting one. Read more...

TOPICS:
Advertisement

Centralized Data Management Improves Collaboration

July 15, 2014 11:16 am | by Dr. Paul Denny-Gouldson, VP of Strategic Solutions at IDBS | Comments

Inventiva, a recent spin-off from Abbott, is a French biotech company specializing in running and managing integrated drug discovery partnerships from target validation up to clinical candidate selection who realized that it would benefit from having a more integrated data processing system across its multiple laboratories. Read more...

TOPICS:

Addressing Side Effects of Mainstream Treatments

July 11, 2014 10:52 am | by Anthony Giovinazzo, President and Chief Executive Officer of Cynapsus Therapeutics Inc. | Comments

The highest-profile symptoms of major diseases are well publicized, yet for many, the side effects of mainstream therapies for these diseases can also impact physical and psychological well-being. Luckily, advances in drug delivery have offered novel treatments. Read more...

TOPICS:

Some 500 Genes Differ in Bipolar Patients’ Neurons

July 2, 2014 3:16 pm | by Cynthia Fox, Science Editor | Comments

Neurons of patients with bipolar disorder (BP) differ from the norm in a “striking” 500 or so genes, according to preliminary data generated using the Nobel-Prize-winning iPSC (induced pluripotent stem cell) approach, by Salk Institute neuroscientist Fred Gage. Read more...

TOPICS:

Innovation Reins in Runaway Pharma Spending

July 1, 2014 1:21 pm | by Nancy Dreyfus, Contributing Science Writer | Comments

To combat the rising costs of bringing a new drug to market, pharmaceutical companies have taken a variety of innovative approaches, according to the U.K. Office of Health Economics, such as deciding earlier in the R&D process to discontinue drugs lacking strong market prospects and better controlling clinical costs. Read more...

TOPICS:

Keeping the Lid on R&D Costs

June 23, 2014 11:14 am | by Nancy Dreyfus, Contributing Science Writer | Comments

In the past, pharmaceutical companies bolstered profits with billion-dollar blockbuster drugs that treated large populations for common conditions, but with patents running out, and development costs soaring, that business model may no longer be sustainable. Read more...

TOPICS:
Advertisement

Neurogenic Drug Improves Depression in Small Trial

June 16, 2014 9:54 am | by Cynthia Fox, Science Editor | Comments

The first small molecule drug discovered with the aid of stem cells - NSI-189, a benzylpiperizine-aminiopyridine - has significantly affected major depressive disorder (MDD) in a small group of patients, Harvard neurologists report this week. Read more...

TOPICS:

Preserving the Future of Drug Discovery

June 9, 2014 9:37 am | by Lori Ball, Chief Operating Officer, BioStorage Technologies | Comments

Biospecimens - and the genetic and genomic information derived from these materials - serve as the framework for the translational medicine research used to develop new drugs, novel biomarkers and personalized molecular diagnostics. Read more...     

TOPICS:

Personalized Cancer Therapies Come of Age

June 3, 2014 8:44 am | by Sean Harper, M.D., Executive Vice President of Research and Development, Amgen | Comments

For many decades, scientific advances in cancer treatment were characterized by a slow, non-linear progress that resulted in treatments with a less than stellar ability to target cancer cells. Now, the advent of biomarker-driven drug development and the drive toward personalized medicine have provided a new approach to the treatment of advanced cancer. Read more...

TOPICS:

Anti-Depressant Reduces Alzheimer’s Plaque Growth by 78%

May 15, 2014 1:32 pm | by Cynthia Fox, Science Editor | Comments

A common antidepressant - the selective serotonin reuptake inhibitor (SSRI) citalopram - can dramatically halt growth of Alzheimer’s plaque, report a team from Missouri and Pennsylvania Wednesday in Science Translational Medicine. Read more...

TOPICS:

AbbVie Eyes Hepatitis C Cure with New Regimen

May 14, 2014 1:47 pm | by Christina Jakubowski, News Editor | Comments

AbbVie is tossing its metaphorical hat into the quickly growing and highly competitive hepatitis C treatment ring with an experimental, all-oral, interferon-free regimen – one that is boasting sustained viral response rates 12 weeks post treatment (SVR12 rates) that range from 90 to 100%. Read more...

TOPICS:

Researchers Find Clue to Cancer Cell Autocannibalism

May 8, 2014 8:30 am | by Cynthia Fox, Science Editor | Comments

Autophagy, where cells "eat" parts of themselves in response to stress, may prompt cancer cells to revive and proliferate in response to chemotherapies— not die— according to a recent Cell Reports study by the University of Colorado Cancer Center. Read more...

TOPICS:

Droplet Digital PCR Advances the Treatment of Cancer

May 6, 2014 9:49 am | by George Karlin-Neumann, Director of Scientific Affairs, Bio-Rad Digital Biology Center, Pleasanton, Calif. | Comments

One of the more exciting new technologies contributing to current advancements in cancer is droplet digital PCR (ddPCR), a method that is already being shown to track both favorable and unfavorable responses to therapy more rapidly than current imaging methods and to enable improved treatments. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading